World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

RLYB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Rallybio Insider Trading History Chart

Rallybio Share Price & Price History

^$1.65

▲ +0.07 (4.43%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Rallybio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2023	Jonathan I Lieber	Insider	Buy	5,000	$5.21	$26,050.00	5,000
3/7/2023	Kush Parmar	Director	Sell	100,000	$8.20	$820,000.00	2,378,969
6/3/2022	Kush Parmar	Director	Sell	150,000	$12.50	$1,875,000.00	1,251,755
5/23/2022	Kush Parmar	Director	Sell	100,000	$13.00	$1,300,000.00	1,302,084
3/21/2022	Jeffrey M. Fryer	Insider	Buy	3,000	$8.04	$24,120.00
2/8/2022	Opportunities I L.P. 5Am	Major Shareholder	Sell	210,000	$13.05	$2,740,500.00
1/19/2022	Jeffrey M. Fryer	Insider	Buy	1,400	$8.70	$12,180.00
1/12/2022	Stephen Uden	Insider	Buy	5,000	$10.55	$52,750.00
1/10/2022	Martin Mackay	CEO	Buy	5,504	$10.10	$55,590.40
1/7/2022	Jeffrey M. Fryer	Insider	Buy	10,000	$9.41	$94,100.00

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

SEC Filings (Institutional Ownership Changes) for Rallybio (NASDAQ:RLYB)

90.34% of Rallybio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Rallybio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
1/31/2024	abrdn plc	1,727,067	$4.13M	0.0%	N/A	4.570%
1/12/2024	SG Americas Securities LLC	16,813	$40K	0.0%	N/A	0.044%
11/13/2023	CHI Advisors LLC	390,734	$1.32M	0.4%	-28.0%	1.034%
11/13/2023	Mariner LLC	408,180	$1.38M	0.0%	-32.7%	1.080%
11/8/2023	Financial Security Advisor Inc.	50,278	$0.17M	0.1%	N/A	0.133%
9/21/2023	Barclays PLC	6,103	$35K	0.0%	-36.3%	0.016%
8/22/2023	CHI Advisors LLC	542,774	$3.07M	0.9%	-28.6%	1.436%
8/15/2023	Caas Capital Management LP	31,470	$0.18M	0.0%	-80.8%	0.083%
8/11/2023	Sectoral Asset Management Inc.	375,960	$2.13M	0.4%	-31.9%	0.995%
8/4/2023	American International Group Inc.	14,715	$83K	0.0%	+62.0%	0.039%
5/12/2023	Sectoral Asset Management Inc.	551,937	$3.15M	0.6%	-11.0%	1.450%
5/11/2023	CHI Advisors LLC	760,543	$4.34M	1.2%	+4.7%	1.997%
4/24/2023	DekaBank Deutsche Girozentrale	30,000	$0.17M	0.0%	N/A	0.079%
2/10/2023	Sectoral Asset Management Inc.	619,891	$4.07M	0.8%	+165.6%	1.935%
2/10/2023	Tekla Capital Management LLC	1,727,067	$11.35M	0.4%	-0.8%	5.392%
2/6/2023	New Leaf Venture Partners L.L.C.	3,301,603	$21.69M	15.7%	+43.4%	10.308%
2/1/2023	Canaan Partners XI LLC	2,059,712	$13.53M	10.6%	-14.5%	6.431%
11/15/2022	Northeast Financial Consultants Inc	13,066	$0.19M	0.0%	N/A	0.041%
11/14/2022	MetLife Investment Management LLC	10,279	$0.15M	0.0%	N/A	0.032%
11/8/2022	New York State Common Retirement Fund	10,337	$0.15M	0.0%	-19.8%	0.032%
11/1/2022	Tekla Capital Management LLC	1,740,931	$25.19M	1.0%	-9.8%	5.418%
8/15/2022	Laurion Capital Management LP	402,000	$3.04M	0.0%	+0.5%	1.251%
8/11/2022	Alps Advisors Inc.	19,060	$0.14M	0.0%	N/A	0.059%
7/29/2022	Tekla Capital Management LLC	1,931,120	$14.58M	0.6%	-12.0%	6.010%
5/27/2022	Walleye Capital LLC	59,543	$0.42M	0.0%	N/A	0.185%
5/13/2022	Tekla Capital Management LLC	2,195,010	$15.32M	0.5%	-4.9%	6.832%
5/10/2022	Sectoral Asset Management Inc.	385,069	$2.69M	0.5%	+27.8%	1.198%
2/9/2022	AJU IB Investment Co. Ltd.	754,678	$7.20M	10.0%	N/A	2.349%
2/8/2022	Northern Trust Corp	61,571	$0.59M	0.0%	+7.1%	0.192%
2/3/2022	Canaan Partners XI LLC	2,409,712	$22.99M	5.9%	N/A	7.500%
1/28/2022	Allspring Global Investments Holdings LLC	2,914	$27K	0.0%	N/A	0.009%
11/16/2021	Laurion Capital Management LP	400,000	$7.03M	0.0%	N/A	1.245%
11/15/2021	Viking Global Investors LP	4,194,777	$73.74M	0.2%	N/A	13.056%
11/15/2021	Sectoral Asset Management Inc	527,136	$9.27M	0.8%	N/A	1.641%
11/15/2021	Caas Capital Management LP	10,000	$0.18M	0.0%	N/A	0.031%
11/12/2021	New Leaf Venture Partners L.L.C.	2,301,603	$40.46M	11.7%	N/A	7.163%
11/12/2021	Geode Capital Management LLC	69,963	$1.23M	0.0%	N/A	0.218%
11/9/2021	BlackRock Inc.	292,204	$5.14M	0.0%	N/A	0.909%
11/4/2021	Deutsche Bank AG	4,139	$73K	0.0%	N/A	0.013%
11/2/2021	New York State Common Retirement Fund	4,396	$77K	0.0%	N/A	0.014%

Data available starting January 2016

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $1.65

$1.54

$1.71

50 Day Range

MA: $1.81

$1.47

$2.98

52 Week Range

Now: $1.65

$1.23

$9.14

Volume

324,537 shs

Average Volume

1,319,172 shs

Market Capitalization

$62.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Rallybio?: Rallybio's top insider investors include:
Kush Parmar (Director)
Jonathan I Lieber (Insider)
Learn More about top insider investors at Rallybio.

Mysterious Gold Leverage Just Announced